Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Valproic acid treatment response in vitro is determined by TP53 status in medulloblastoma

Full text
Mascaro-Cordeiro, Bruna [1, 2] ; Oliveira, Indhira Dias [1] ; Tesser-Gamba, Francine [1] ; Pavon, Lorena Favaro [3] ; Saba-Silva, Nasjla [1] ; Cavalheiro, Sergio [1, 3] ; Dastoli, Patricia [1] ; Caminada Toledo, Silvia Regina [1, 2]
Total Authors: 8
[1] UNIFESP Fed Univ Sao Paulo, GRAACC Grp Apoio Adolescente & Crianca Canc, Pediat Oncol Inst, Genet Lab, Rua Botucatu 743, Floor 8, BR-04023062 Sao Paulo, SP - Brazil
[2] Univ Fed Sao Paulo, Div Genet, Dept Morphol & Genet, Sao Paulo, SP - Brazil
[3] Univ Fed Sao Paulo, Dept Neurol, Sao Paulo, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: CHILD'S NERVOUS SYSTEM; v. 34, n. 8, p. 1497-1509, AUG 2018.
Web of Science Citations: 0

Histone deacetylate inhibitors (HDACi), as valproic acid (VA), have been reported to enhance efficacy and to prevent drug resistance in some tumors, including medulloblastoma (MB). In the present study, we investigated VA role, combined to cisplatin (CDDP) in cell viability and gene expression of MB cell lines. Dose-response curve determined IC50 values for each treatment: (1) VA single, (2) CDDP single, and (3) VA and CDDP combined. Cytotoxicity and flow cytometry evaluated cell viability after exposure to treatments. Quantitative PCR evaluated gene expression levels of AKT, CTNNB1, GLI1, KDM6A, KDM6B, NOTCH2, PTCH1, and TERT , before and after treatment. Besides, we performed next-generation sequencing (NGS) for PTCH1, TERT, and TP53 genes. The most effective treatment to reduce viability was combined for D283MED and ONS-76; and CDDP single for DAOY cells (p < 0.0001). TERT, GLI1, and AKT genes were overexpressed after treatments with VA. D283MED and ONS-76 cells presented variants in TERT and PTCH1, respectively and DAOY cell line presented a TP53 mutation. MB tumors belonging to SHH molecular subgroup, with TP53(MUT), would be the ones that present high risk in relation to VA use during the treatment, while TP53(WT) MBs can benefit from VA therapy, both SHH and groups 3 and 4. Our study shows a new perspective about VA action in medulloblastoma cells, raising the possibility that VA may act in different patterns. According to the genetic background of MB cell, VA can stimulate cell cycle arrest and apoptosis or induce resistance to treatment via signaling pathways activation. (AU)

FAPESP's process: 13/12281-4 - Identification of a panel of mutations and histone methylation patterns in Medulloblastoma of childhood and adolescence
Grantee:Bruna Mascaro Cordeiro de Azevedo
Support Opportunities: Scholarships in Brazil - Doctorate